

CHAPTER ONE: INTRODUCTION	1
OBJECTIVES AND GOALS OF STUDY.....	1
INTENDED AUDIENCE.....	2
SCOPE OF REPORT	2
METHODOLOGY	3
INFORMATION SOURCES.....	3
ANALYST CREDENTIALS.....	3
RELATED BCC REPORTS	3
BCC ONLINE SERVICES.....	4
DISCLAIMER	4
CHAPTER TWO: SUMMARY.....	5
SUMMARY (CONTINUED).....	5
<i>SUMMARY TABLE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, THROUGH 2014 (\$ MILLIONS)</i>	6
<i>SUMMARY FIGURE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, 2007- 2014 (\$ MILLIONS)</i>	6
CHAPTER THREE: OVERVIEW AND OVERALL STATUS OF THE INDUSTRY	7
TOTAL SCOPE OF REGENERATIVE MEDICINE MARKET.....	7
<i>TABLE 1 FUNCTIONAL ACTIVITIES WITH REGENERATIVE MEDICINE SECTOR</i>	8
HOW REGENERATIVE MEDICINE WORKS	8
TISSUES AND ORGANS ON DEMAND.....	9
ORGAN REPLACEMENT IS A \$100 BILLION PER YEAR BUSINESS	10
EXAMPLES OF IMPACT ON EXISTING CONDITIONS AND DISEASES.....	10
BARRIERS TO REGENERATIVE MEDICINE	11
CURRENT R&D PRIORITIES.....	12
<i>TABLE 2 PRINCIPAL REGENERATIVE MEDICINE BUSINESS R&D FOCUSES</i>	13
<i>TABLE 3 20-YEAR PLANNING HORIZON FOR REGENERATIVE MEDICINE BUSINESS: LIKELY DEVELOPMENTS, 2015-2030</i>	14
TOTAL OUTPUT OF THE SECTOR.....	15
REGENERATIVE MEDICINE AND HEALTHCARE ECONOMICS.....	15
POPULATION TRENDS	16
MARKET TIMING	16
OVERSEAS INITIATIVES.....	17
CHAPTER FOUR: PRINCIPLE APPROACHES TO REGENERATIVE MEDICINE	18

PRINCIPLE APPROACHES TO REGENERATIVE MEDICINE	18
HUMAN SUBSTANCES	19
CELLS AND TISSUES	19
TISSUE ENGINEERING	19
Importance of Scaffolding in Tissue Engineering	20
Blood Vessel Scaffolding.....	21
Center for Integration of Medicine and Innovative Technology (CIMIT)	21
<i>TABLE 4 PRINCIPLE RESEARCH PROJECTS OF CIMIT IN THE TISSUE-ENGINEERING AND BIOMATERIALS FIELDS, 2008–2010.....</i>	<i>22</i>
Massachusetts General Hospital	22
Duke University Stem Cell and Regenerative Medicine Program	23
EMBRYONIC STEM CELLS	23
THERAPEUTIC CLONING	24
ADULT STEM CELLS: JUST AS GOOD AS EMBRYONIC STEM CELLS.....	24
GENZYME.....	24
UNIVERSITY OF MINNESOTA STEM CELL INSTITUTE.....	25
STEM CELL RESEARCH PATENTS AND EFFECT ON STEM CELL MARKETERS.....	26
SETTING THE STAGE FOR REGENERATIVE MEDICINE TO TREAT BONE AND JOINT DISORDERS.....	26
NOVEL MATERIALS	27
GENE THERAPY.....	27
Gene Therapy Trials Targeting Bone and Joint Diseases and Disorders	28
BIOREACTOR USE IN REGENERATIVE MEDICINE.....	29
<i>TABLE 5 COMMERCIAL SUPPLIERS OF BIOREACTORS FOR USE IN REGENERATIVE MEDICINE.....</i>	<i>29</i>
THE IMPACT OF GENOMICS.....	30
CHAPTER FIVE: PRODUCTS AND TECHNOLOGIES: CATEGORIES OF REGENERATIVE MEDICINE.....	31
GENE- AND PROTEIN-BASED APPROACHES	31
ANTIBODIES.....	31
The Importance of Antibody Drugs.....	32
Advantages of Monoclonal Antibody Drugs	33
Antibodies and Osteoarthritis.....	34
GROWTH FACTORS.....	35
GROWTH FACTORS (CONTINUED)	36
HOW BMPs FUNCTION.....	37
<i>TABLE 6 BONE MORPHOGENETIC PROTEINS.....</i>	<i>38</i>
Clinical Uses	38
Companies.....	39

CELLS AND TISSUES	40
TISSUE ENGINEERING	40
ARTIFICIAL SKIN	41
CARTILAGE.....	42
OTHER APPROACHES TO CARTILAGE.....	43
BIOSYNTHETIC COMPOSITES FOR CARTILAGE REPAIR	44
THE MARKET FOR TISSUE-ENGINEERED CARTILAGE PRODUCTS.....	44
<i>TABLE 7 U.S. MARKET FOR TISSUE-ENGINEERED CARTILAGE PRODUCTS, THROUGH 2014 (\$ MILLIONS).....</i>	<i>45</i>
OTHER PRODUCTS	45
CREATION OF ENTIRE ORGANS	45
CREATION OF ENTIRE ORGANS (CONTINUED).....	46
EMBRYONIC STEM CELLS	47
NOVEL MATERIALS AND BIOMATERIALS.....	48
 CHAPTER SIX: STEM CELL THERAPIES AND REGENERATIVE MEDICINE	 49
STEM CELLS AS POTENTIAL REPLACEMENT CELLS	49
TECHNICAL IMPEDIMENTS	50
OVERVIEW OF FUNDING.....	51
<i>TABLE 8 FEDERAL FUNDING FOR STEM CELL RESEARCH, THROUGH 2008 (\$ MILLIONS).....</i>	<i>52</i>
STATE-LEVEL INITIATIVES FOR STEM CELL RESEARCH	52
<i>TABLE 9 STATE LEVEL PROGRAMS FOCUSED ON STEM CELL RESEARCH.....</i>	<i>53</i>
POTENTIAL APPLICATIONS: CURRENT STATUS	53
<i>IN VIVO</i> REPROGRAMMING	54
UMBILICAL CORD BLOOD STEM CELLS	55
Recent Research Developments	55
INDUCED PLURIPOTENT STEM CELLS.....	56
Recent Research Developments	56
Adult Multipotent Stem Cells	57
Embryonic Stem Cells	57
Embryonic Stem Cells (Continued).....	58
GERON AND THE FIRST HUMAN TRIALS	59
GERON AND THE FIRST HUMAN TRIALS (CONTINUED).....	60
OTHER STEM CELL RESEARCH	61
STATUS OF OTHER CLINICAL TRIALS	62
STEM CELL THERAPY FOR ALS	63
STEM CELL THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY	64
STEM CELL THERAPY AND BONE MARROW TRANSPLANTS.....	65
Stem Cell Therapy and ... (Continued)	66

CHAPTER SEVEN: REGENERATIVE PRODUCTS TO TREAT BONE

DISEASES	67
REGENERATIVE PRODUCTS TO TREAT BONE DISEASES	67
OSTEOBIOLOGICS.....	67
BONE GRAFTS.....	68
<i>TABLE 10 CHARACTERISTICS OF IDEAL BONE GRAFT MATERIAL</i>	69
<i>TABLE 11 U.S. BONE GRAFT PROCEDURE VOLUMES BY APPLICATION, THROUGH 2014</i>	70
<i>TABLE 12 U.S. BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, THROUGH 2014</i>	70
<i>TABLE 13 BONE GRAFT MATERIALS</i>	71
<i>TABLE 13 (CONTINUED)</i>	72
<i>TABLE 14 SUBSTITUTE BONE GRAFTS</i>	72
AUTOGRAFTS	73
BIOSEED GRAFTS.....	73
ALLOGRAFTS.....	74
Allografts (Continued)	75
DEMINERALIZED BONE MATRIX PRODUCTS	76
<i>TABLE 15 SELECTED DBM PRODUCTS AND PERCENTAGE OF DEMINERALIZED BONE MATRIX</i>	77
Accell	77
AlphaGRAFT	77
Allomatrix	78
Grafton DBM	78
DBX	78
DynaBlast and DynaGraft-D	78
Graftech	78
Grafton	78
Opteform	79
OrthoBlast II.....	79
Osteofil	79
Solo Cervical Allograft.....	80
XENOGRAFTS	80
THE MARKET FOR ALLOGRAFTS	80
<i>TABLE 16 U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, THROUGH 2014 (\$ MILLIONS)</i>	80
<i>FIGURE 1 U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, 2007-2014 (\$ MILLIONS)</i>	81
CELL-BASED BONE GRAFT SUBSTITUTES.....	82
FACTOR-BASED BONE GRAFT SUBSTITUTES.....	82
Factor-based Bone Graft Substitutes (Continued).....	83
BONE MORPHOGENIC PROTEINS	84
INDUCTOS.....	84
INFUSE BONE GRAFT.....	85

OP-1 IMPLANT	85
CERAMIC-BASED BONE GRAFT SUBSTITUTES	86
TYPES OF CERAMICS	86
Alpha-BSM	87
BioGran	87
Bio-Oss	88
BoneSource	88
Calcigen S	88
Collagraft Strip Bone Graft Matrix	88
Conduit TCP Granules	89
IsoTis Products	89
Mimix Bone Substitute Material	90
Norian SRS	90
OsteoGraf	90
Osteoset	90
OsteoStim Resorbable Bone Graft Substitute	91
PerioGlas	91
Pro Osteon Implant	91
Vitoss	91
POLYMER-BASED BONE GRAFT SUBSTITUTES	92
CORTOSS	92
HEALOS	93
IMMIX EXTENDERS AND IMMIX CB	94
THE MARKET FOR BONE GRAFT PRODUCTS	94
<i>TABLE 17 WORLDWIDE MARKET FOR BONE REPLACEMENT</i>	
<i>PRODUCTS, THROUGH 2014 (\$ MILLIONS)</i>	94
<i>FIGURE 2 WORLDWIDE MARKET FOR BONE REPLACEMENT</i>	
<i>PRODUCTS, 2007-2014 (\$ MILLIONS)</i>	95
<i>TABLE 18 U.S. MARKET FOR BONE-REPLACEMENT PRODUCTS,</i>	
<i>THROUGH 2014 (\$ MILLIONS)</i>	96
<i>FIGURE 3 U.S. MARKET FOR BONE-REPLACEMENT PRODUCTS,</i>	
<i>2007-2014 (\$ MILLIONS)</i>	96
REGENERATIVE MEDICINE PRODUCTS IN DEVELOPMENT FOR	
BONE APPLICATIONS	96
BIOLOGIC/SYNTHETIC GRAFTS	97
CHRYSSALIN	97
Chryssalin (Continued)	98
Chryssalin (Continued)	99
 CHAPTER EIGHT: REGENERATIVE APPLICATIONS FOR BONES AND	
JOINTS	100
MATERIALS FOR BONE TISSUE REPAIR	100
INHERENT REGENERATION OF BONE	100
OVERALL SIZE OF BONE GRAFT BUSINESS	101
BONE GRAFT SUBSTITUTES	102

ALLOGRAFT TISSUE.....	103
OTHER OSTEOCONDUCTIVE BONE GRAFT SUBSTITUTES.....	104
HYDROGELS AND REGENERATION.....	105
COMPOSITION AND METHOD FOR SELF-ASSEMBLY AND MINERALIZATION OF PEPTIDE AMPHIPHILES	106
CHONDROITINASE ABC I POLYNUCLEOTIDES.....	107
Abstract.....	107
TRANSDISCAL ADMINISTRATION OF CYCLINE COMPOUNDS.....	107
Abstract.....	107
COMPOSITION AND METHOD FOR PREPARING BIOCOMPATIBLE SURFACES	108
Abstract.....	108
SPINAL MOBILITY PRESERVATION APPARATUS HAVING AN EXPANDABLE MEMBRANE	108
Abstract.....	108
MAJOR DISEASES AND CONDITIONS AFFECTING BONES.....	109
OSTEOPOROSIS	110
Currently Available Products to Treat Osteoporosis	111
Bisphosphonates	111
Fosamax.....	112
Boniva	113
<i>TABLE 19 DRUGS USED TO TREAT OSTEOPOROSIS.....</i>	<i>113</i>
Hormones	114
Evista.....	114
Forteo.....	114
Forteo (Continued)	115
Forteo (Continued)	116
Miacalcin	117
STEROIDS AND OSTEOPOROSIS	117
Glucocorticoids.....	118
THE MARKET FOR PRODUCTS TO TREAT OSTEOPOROSIS.....	118
<i>TABLE 20 WORLDWIDE MARKET FOR DRUGS TO TREAT OSTEOPOROSIS, THROUGH 2014 (\$ MILLIONS).....</i>	<i>119</i>
<i>FIGURE 4 WORLDWIDE MARKET FOR DRUGS TO TREAT OSTEOPOROSIS, 2007-2014 (\$ MILLIONS).....</i>	<i>119</i>
PAGET'S DISEASE	119
DRUGS CURRENTLY AVAILABLE TO TREAT PAGET'S DISEASE.....	120
Actonel.....	120
Aredia	120
Skelid	121
Zometa.....	121
THE MARKET FOR PRODUCTS TO TREAT PAGET'S DISEASE	121

<i>TABLE 21 WORLDWIDE MARKET FOR DRUGS TO TREAT PAGET'S DISEASE, THROUGH 2014 (\$ MILLIONS)</i>	121
<i>FIGURE 5 WORLDWIDE MARKET FOR DRUGS TO TREAT PAGET'S DISEASE, 2007-2014 (\$ MILLIONS)</i>	122
INJURIES AND DEGENERATIVE CONDITIONS	122
HIP FRACTURES	123
<i>TABLE 22 WORLDWIDE HIP FRACTURE VOLUMES, THROUGH 2014</i>	124
<i>TABLE 23 U.S. HIP FRACTURE VOLUMES, THROUGH 2014</i>	124
TRADITIONAL TREATMENTS FOR BONE AND JOINT DISORDERS	124
<i>TABLE 24 U.S. MARKET SHARES FOR MUSCULOSKELETAL PRODUCTS, 2008 (%)</i>	125
<i>TABLE 25 U.S. RECONSTRUCTIVE DEVICE MARKET, 2008 (%)</i>	125
MARKET LEADERS.....	125
JOINT-REPLACEMENT SURGERY.....	126
<i>TABLE 26 HIP REPLACEMENT PROCEDURE VOLUMES, U.S., THROUGH 2014</i>	126
<i>TABLE 27 HISTORICAL RATES OF HIP REPLACEMENT IN SIX MAJOR STATES, 2001</i>	126
<i>TABLE 28 WORLDWIDE HIP REPLACEMENT MARKET, THROUGH 2014 (\$ MILLIONS)</i>	127
<i>FIGURE 6 WORLDWIDE HIP REPLACEMENT MARKET, 2007-2014 (\$ MILLIONS)</i>	127
<i>TABLE 29 U.S. HIP REPLACEMENT MARKET, THROUGH 2014 (\$ MILLIONS)</i>	127
<i>FIGURE 7 U.S. HIP REPLACEMENT MARKET, 2007-2014 (\$ MILLIONS)</i>	128
KNEE REPLACEMENTS	128
<i>TABLE 30 WORLDWIDE KNEE-REPLACEMENT PROCEDURE VOLUMES, THROUGH 2014</i>	129
<i>TABLE 31 U.S. KNEE REPLACEMENT PROCEDURE VOLUMES, THROUGH 2014</i>	129
<i>TABLE 32 WORLDWIDE KNEE REPLACEMENT MARKET, THROUGH 2014 (\$ MILLIONS)</i>	129
<i>FIGURE 8 WORLDWIDE KNEE REPLACEMENT MARKET, 2007-2014 (\$ MILLIONS)</i>	130
<i>TABLE 33 U.S. KNEE REPLACEMENT MARKET, THROUGH 2014 (\$ MILLIONS)</i>	130
<i>FIGURE 9 U.S. KNEE REPLACEMENT MARKET, 2007-2014 (\$ MILLIONS)</i>	131
<i>TABLE 34 U.S. MARKET FOR UNICONDYLAR KNEE REPLACEMENT, THROUGH 2014 (\$ MILLIONS)</i>	131
<i>FIGURE 10 U.S. MARKET FOR UNICONDYLAR KNEE REPLACEMENT, 2007-2014 (\$ MILLIONS)</i>	132

NATURAL THERAPEUTIC TREATMENTS FOR ARTHRITIS	132
IMAGING AND REGENERATION	133
IMAGING AND REGENERATION (CONTINUED).....	134
 CHAPTER NINE: ELECTRICAL BONE GROWTH STIMULATOR	
MARKET	135
OVERVIEW.....	135
SCIENTIFIC BASIS	136
ULTRASONIC OSTEOGENESIS STIMULATORS FOR BONE HEALING	137
MARKETERS OF INVASIVE AND NONINVASIVE ELECTRICAL BONE GROWTH STIMULATORS.....	138
BIOMET.....	138
ORTHOFIX.....	139
DJO, INC.	140
SMITH & NEPHEW	141
MARKET SIZE.....	141
TABLE 35 WORLDWIDE MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2014 (\$ MILLIONS).....	141
TABLE 36 U.S. MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2007 (\$ MILLIONS).....	142
 CHAPTER TEN: ORTHOPEDICS—FDA CLEARANCES AND NEW PRODUCT DEVELOPMENT	
SUPPLIERS OF REGENERATIVE BONE AND JOINT PRODUCTS.....	143
TABLE 37 RECENTLY APPROVED ORTHOPEDIC BONE AND JOINT DEVICES BY PRODUCT, COMPANY, AND APPROVAL DATE, 2008– 2009.....	144
TABLE 37 (CONTINUED).....	145
TABLE 37 (CONTINUED).....	146
TABLE 37 (CONTINUED).....	147
TABLE 37 (CONTINUED).....	148
TABLE 37 (CONTINUED).....	149
TABLE 37 (CONTINUED).....	150
TABLE 37 (CONTINUED).....	151
TABLE 37 (CONTINUED).....	152
TABLE 37 (CONTINUED).....	153
TABLE 37 (CONTINUED).....	154
TABLE 37 (CONTINUED).....	155
TABLE 37 (CONTINUED).....	156
TABLE 37 (CONTINUED).....	157
TABLE 37 (CONTINUED).....	158
 CHAPTER ELEVEN: MARKET FOR TISSUE ENGINEERING PRODUCTS	
TISSUE ENGINEERING AND CELL THERAPY	159

RESEARCH INITIATIVES	160
RESEARCH INITIATIVES (CONTINUED).....	161
RESEARCH INITIATIVES (CONTINUED).....	162
CHAPTER TWELVE: REGENERATIVE CONCEPTS AND PRODUCTS IN DENTISTRY	163
OVERVIEW.....	163
INDICATIONS AND HISTORY.....	163
CHARACTERISTICS AND MATERIALS.....	164
BARRIER MEMBRANES	164
NON-RESORBABLE	164
RESORBABLE	164
COLLAGEN RESORBABLE MEMBRANES	165
SYNTHETIC RESORBABLE MEMBRANES	165
CHAPTER THIRTEEN: SKIN TECHNOLOGIES	166
SKIN TECHNOLOGIES (CONTINUED).....	166
SKIN-LIKE TISSUE DEVELOPED FROM HUMAN EMBRYONIC STEM CELLS	167
<i>TABLE 38 SALES OF ENGINEERED SKIN GRAFTS AND REPLACEMENTS, THROUGH 2014 (\$ MILLIONS)</i>	168
CHAPTER FOURTEEN: NEUROLOGICAL APPLICATIONS IN REGENERATIVE MEDICINE.....	169
OVERVIEW.....	169
NEURODEGENERATIVE DISEASES.....	169
CURRENT CONVENTIONAL THERAPIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE SYMPTOMS	169
SPINAL CORD INJURY, NEURODEGENERATIVE DISEASES, AND REGENERATIVE POTENTIAL.....	170
SPINAL CORD INJURY, ... (CONTINUED)	171
UNIVERSITY OF SOUTHERN CALIFORNIA (USC).....	172
CHAPTER FIFTEEN: REGENERATIVE MEDICINE AND APPLICATIONS IN CARDIAC CARE.....	173
OVERVIEW.....	173
STEM CELLS FOR THE FUTURE TREATMENT OF HEART DISEASE.....	173
PARTICULAR R&D PRIORITIES.....	174
PARTICULAR R&D PRIORITIES (CONTINUED)	175
STEM CELLS AND BIOLOGICAL PACEMAKERS	176
HEART PROGENITOR CELLS DEVELOPED FROM EMBRYONIC STEM CELLS	176
OTHER CURRENT REGENERATIVE MEDICINE AS IT RELATES TO THE HEART.....	177

OTHER CURRENT REGENERATIVE ...(CONTINUED)	178
CHAPTER SIXTEEN: REGENERATIVE MEDICINE AND DIABETES	179
BACKGROUND	179
POSSIBLE APPLICATIONS FOR REGENERATIVE MEDICINE	179
POSSIBLE APPLICATIONS FOR ... (CONTINUED)	180
CHAPTER SEVENTEEN: FDA APPROVED CLINICAL TRIALS	
INVOLVING REGENERATIVE MEDICINE	181
CURRENT STATUS OF THE REGENERATIVE MEDICINE	
BUSINESS	181
REGULATORY ENVIRONMENT	181
REGULATORY ENVIRONMENT (CONTINUED)	182
STATUS OF RESEARCH AND CLINICAL TRIALS	183
ANALYSIS OF CLINICAL TRIALS	184
TABLE 39 REGENERATIVE MEDICINE CLINICAL TRIALS BY	
MAJOR CATEGORY	185
TABLE 40 CURRENT CLINICAL TRIALS IN THE FIELD OF	
REGENERATIVE MEDICINE STATUS, CONDITIONS,	
INTERVENTION, AND SPONSOR	185
TABLE 40 (CONTINUED)	186
TABLE 40 (CONTINUED)	187
TABLE 40 (CONTINUED)	188
TABLE 40 (CONTINUED)	189
TABLE 40 (CONTINUED)	190
TABLE 40 (CONTINUED)	191
TABLE 40 (CONTINUED)	192
TABLE 40 (CONTINUED)	193
TABLE 40 (CONTINUED)	194
TABLE 40 (CONTINUED)	195
TABLE 40 (CONTINUED)	196
TABLE 40 (CONTINUED)	197
TABLE 40 (CONTINUED)	198
TABLE 40 (CONTINUED)	199
TABLE 40 (CONTINUED)	200
TABLE 40 (CONTINUED)	201
TABLE 40 (CONTINUED)	202
TABLE 40 (CONTINUED)	203
TABLE 40 (CONTINUED)	204
TABLE 40 (CONTINUED)	205
TABLE 40 (CONTINUED)	206
TABLE 40 (CONTINUED)	207
TABLE 40 (CONTINUED)	208
TABLE 40 (CONTINUED)	209

CHAPTER EIGHTEEN: OVERSEAS ACTIVITIES.....	210
DOMESTIC VERSUS OVERSEAS REGENERATIVE MEDICINE	
COMPANIES	210
JAPAN	210
EUROPE.....	211
AUSTRALIA AND CHINA	212
CHAPTER NINETEEN: PATENT ANALYSIS.....	213
ANALYSIS	213
TISSUE ENGINEERING PATENTS.....	213
<i>TABLE 41 MOST FREQUENTLY CITED PATENT ASSIGNEES IN</i>	
<i>TISSUE ENGINEERING FIELD</i>	214
GEOGRAPHIC DISTRIBUTION	214
<i>TABLE 42 WORLD DISTRIBUTION OF REGENERATIVE MEDICINE</i>	
<i>PATENTS ISSUED, 1985–2009 (%)</i>	215
RECENT PATENTS	215
DIRECT DIFFERENTIATION METHOD FOR MAKING	
CARDIOMYOCYTES FROM HUMAN EMBRYONIC STEM	
CELLS	215
Abstract.....	215
METHOD FOR PREPARING NOVEL TRANSCRIPTION	
FACTORS AND USE.....	216
Abstract.....	216
ENDODERM CELLS FROM HUMAN EMBRYONIC STEM	
CELLS	216
Abstract.....	216
GENES WITH ES CELL-SPECIFIC EXPRESSION	217
Abstract.....	217
MARKER SYSTEM FOR PREPARING AND	
CHARACTERIZING HIGH-QUALITY HUMAN	
EMBRYONIC STEM CELLS	217
Abstract.....	217
CHAPTER TWENTY: COMPANY PROFILES.....	218
<i>TABLE 43 PUBLICALLY TRADED COMPANIES IN THE</i>	
<i>REGENERATIVE MEDICINE INDUSTRY, AS OF JULY 1, 2009</i>	218
AASTROM BIOSCIENCES, INC.	219
ADVANCED BIOHEALING, INC.....	219
ADVANCED CELL TECHNOLOGY, INC.....	220
AESCULAP, INC.	221
ALDAGEN, INC.....	221
ALPHATEC SPINE, INC.	222
ANGIOTECH PHARMACEUTICALS, INC.	222
ARTERIOCYTE MEDICAL SYSTEMS, INC.	223
ARTHREX, INC.	223

ARTHROCARE CORPORATION	223
BIOMET, INC.	224
BIOMIMETIC THERAPEUTICS, INC.....	224
BIOTISSUE TECHNOLOGIES GMBH.....	224
CAPSTONE THERAPEUTICS	225
CENTERPULSE ORTHOPAEDICS, INC.	226
CERAPEDICS, INC.	226
CITAGENIX, INC.	226
CONMED CORPORATION.....	227
CROSSCART INC.....	228
CRYOLIFE, INC.	229
CURIS.....	230
CYTORI THERAPEUTICS, INC.....	231
DEPUY ORTHOPAEDICS, INC. (UNIT OF THE DEPUY COMPANIES).....	231
DJO SURGICAL	232
ESBATECH AG.....	232
ETEX CORPORATION.....	233
EXACTECH, INC.....	234
FATE THERAPEUTICS, INC.....	234
GARNET BIOTHERAPEUTICS	234
GENZYME BIOSURGERY	235
GERON CORPORATION	236
INTEGRA LIFESCIENCES HOLDING CORP.....	236
ISOTIS ORTHOBIOLOGICS, INC. (INTEGRA ORTHOBIOLOGICS)	237
INTERNATIONAL STEM CELL	237
INTERPORE CROSS INTERNATIONAL.....	238
ISTO TECHNOLOGIES, INC.	239
KENSEY NASH CORPORATION	240
LIFECELL (A SUBSIDIARY OF KINETIC CONCEPTS, INC.).....	241
MCEWEN CENTRE FOR REGENERATIVE MEDICINE.....	241
MCGOWAN INSTITUTE FOR REGENERATIVE MEDICINE.....	242
MEDTRONIC, INC.	242
MESOBLAST, LIMITED	243
NATIONAL CENTER FOR REGENERATIVE MEDICINE	243
NATIONAL TISSUE ENGINEERING CENTER (NTEC).....	244
NEURALSTEM.....	245
NOVABONE PRODUCTS, LLC.....	246
NOVARTIS CORPORATION	246
NOVOCELL, INC.	246
OPEXA THERAPEUTICS.....	246
ORGANOGENESIS INC.	247
ORTHOFIX INTERNATIONAL N.V.	248
ORTHOPEUTICS, L.P.....	248

ORTHOVITA, INC.....	249
OSIRIS THERAPEUTICS, INC.....	249
OSTEOTECH, INC.....	250
PFIZER, INC.....	250
PLURISTEM THERAPEUTICS	250
REGEN BIOLOGICS, INC.....	251
RENEURON.....	252
RTI BIOLOGICS, INC.....	252
SCIL TECHNOLOGY GMBH	252
SMITH AND NEPHEW.....	253
STEMCELLS, INC.....	253
STEMCOR SYSTEMS, INC.....	254
STRAUMANN USA LLC.....	254
STRYKER CORP.	255
SYNTHES, INC.....	255
TENGION.....	256
TEPHA	257
THERMOGENESIS CORP.....	257
TIGENIX N.V.....	258
UCB S.A. (HEADQUARTERS).....	259
WAKE FOREST INSTITUTE FOR REGENERATIVE MEDICINE.....	259
WRIGHT MEDICAL GROUP, INC.....	260
ZIMMER HOLDINGS, INC.....	261
OTHER ORGANIZATIONS INVOLVED IN REGENRERATIVE MEDICINE R&D	261
ACADEMIC INSTITUTIONS.....	261
U.S. GOVERNMENT	262
OTHER SOCIETIES AND ORGANIZATIONS	262

CHAPTER TWENTY-ONE: GLOSSARY OF KEY TERMS IN

REGENERATIVE MEDICINE BUSINESS.....	263
GLOSSARY OF KEY TERMS	263
GLOSSARY OF KEY TERMS (CONTINUED).....	264
GLOSSARY OF KEY TERMS (CONTINUED).....	265
GLOSSARY OF KEY TERMS (CONTINUED).....	266
GLOSSARY OF KEY TERMS (CONTINUED).....	267
GLOSSARY OF KEY TERMS (CONTINUED).....	268
GLOSSARY OF KEY TERMS (CONTINUED).....	269